Form 4: REGENXBIO CFO Sells Shares for Tax Obligations

REGENXBIO Inc.'s Chief Financial Officer, Mitchell Chan, disposed of 4,901 common shares to cover tax liabilities related to vested restricted stock units.

Summary

• Mitchell Chan, Chief Financial Officer of REGENXBIO Inc., reported a transaction on September 1, 2025.
• The transaction involved the disposition of 4,901 shares of common stock.
• These shares were withheld to satisfy tax obligations upon the vesting of restricted stock units.
• The restricted stock units were originally granted to the reporting person on September 16, 2024.
• The shares were valued at $8.93 per share, based on the closing price of the issuer's common stock on August 29, 2025.
• Following this transaction, Mitchell Chan beneficially owns 53,968 shares of REGENXBIO Inc. common stock.

Sentiment

Score: 6

Explanation: The transaction is a routine tax-related disposition of shares upon the vesting of restricted stock units, reflecting the execution of a pre-existing compensation plan rather than a discretionary sale or a change in company fundamentals. This is a neutral to slightly positive event as it confirms the vesting of executive compensation.

Positives

• Vesting of restricted stock units indicates the fulfillment of employment conditions and a component of executive compensation, which is generally a positive for employee retention and motivation.

Negatives

• The direct beneficial ownership of the Chief Financial Officer, Mitchell Chan, was reduced by 4,901 shares.

Future Outlook

This filing, an SEC Form 4, does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing details a routine insider transaction where an executive disposes of shares to cover tax liabilities upon the vesting of restricted stock units. This is a common occurrence across all industries for executives receiving equity compensation and does not typically indicate a change in company strategy or performance, but rather the execution of a pre-existing compensation plan.

Comparison to Industry Standards

• This type of transaction (shares withheld for tax upon RSU vesting) is a standard practice for executive equity compensation across public companies in various industries, including biotechnology. It aligns with common compensation structures designed to incentivize and retain key personnel.

Related Party Transactions

• Disposition of shares by CFO Mitchell Chan to cover tax obligations arising from the vesting of restricted stock units, which is a transaction between an officer and the company related to compensation.

Stakeholder Impact

• Shareholders: The transaction is a routine compliance filing related to executive compensation and is unlikely to have a significant direct impact on the company's share price or valuation. It confirms the execution of previously disclosed equity compensation plans.
• Employees: Reinforces the company's equity compensation structure for executives, demonstrating the realization of value from long-term incentive plans.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by the CFO to cover tax obligations upon the vesting of restricted stock units. Such transactions are common and do not typically signal a change in the company's fundamental outlook or the insider's confidence. Therefore, it provides no new information that would warrant a change in investment recommendation.

Keywords

REGENXBIO, RGNX, Mitchell Chan, CFO, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, Equity Compensation